Effect of sintilimab combined with anlotinib hydrochloride on serum immune indexes and tumor markers in patients with advanced non-small cell lung cancer
Objective:To investigate the effects of the combination of sintilimab and anlotinib hydrochlo-ride on serum immunological indicators and tumor marker levels in patients with advanced non-small cell lung cancer.Methods:80 patients with advanced non-small cell lung cancer were selected as the study subjects and randomly assigned to the study group(n =40)and control group(n =40).The control group patients were treated with oral anlotinib,while the study group patients were treated with the combination of sintilimab and anlotinib.The clinical efficacy,serum immunological indicators,tumor marker levels,and adverse reaction incidence were compared between the two groups.Results:In terms of clinical efficacy indicators,there was no significant difference in objective response rate between the study group and the control group(P＞0.05),but the disease control rate was higher in the control group(P＜0.05).After intervention,both groups had higher CD4+and CD4+/CD8+levels than before intervention,with the study group having higher levels than the con-trol group(P＜0.05).Both groups had lower CD8+levels than before intervention,with the study group hav-ing lower levels than the control group(P＜0.05).The expression levels of MMP2,VEGF,TIMP-1,and CY211 were all lower than before intervention in both groups,with the study group having lower levels than the control group(P＜0.05).There was no significant difference in adverse reaction incidence between the two groups(P＞0.05).Conclusion:The combination of sintilimab and anlotinib hydrochloride can improve pa-tient immunological levels and reduce tumor marker levels in patients with advanced non-small cell lung canc-er.The treatment is effective and has certain safety.
XindilizumabNon-small cell lung cancerAnlotinib hydrochlorideTumor markersIm-mune function
NETL
NSTL
万方数据
维普
